To evaluate BNCT therapeutic efficacy in vitro and in vivo at the proton linear accelerator-based neutron generator (DM-BNCT), we needed to establish factors such as BPA treatment concentration and time, boron concentration in cells and tumor, and neutron irradiation time point. This evidence concerns the gene DST and neoplasm.